Illumina has partnered with Vitrolife to sell our preimplantation genetic screening (PGS) and karyomapping products. Please contact Vitrolife for any sales and support.
HumanKaryomap-12 DNA Analysis Kit
This genome-wide karyomapping microarray provides insight into the inheritance of single-gene defects by testing single cells from embryo biopsies.
Read More...
Total:
Product Highlights
The HumanKaryomap-12 DNA Analysis Kit is a comprehensive genome-wide test available at the single-cell level. It provides insight into the inheritance of single-gene defects.
This BeadChip array targets ~300,000 of the most informative markers in the genome for efficient genome-wide coverage1. Karyomapping uses biomarkers within the genome to assess the likelihood of an embryo carrying a gene variant involved in a single-gene disorder.
The karyomapping technique can create a complete map of the in vitro embryo chromosomes, giving researchers valuable insight into the role that genomics plays in the inheritance of single-gene defects. This method uses SNP (single nucleotide polymorphisms) array technology to confirm the presence or absence of a specific allele.
Frequently Purchased Together
Specifications
Product Literature
An Introduction to Illumina Next-Generation Sequencing Technology for HLA Analysis
White paper | PDF < 1 MB
A dedicated support section is not currently available for this product
The SureMDA Amplification System has been discontinued. The REPLI-g Single Cell Kit (QIAGEN) is the suggested replacement for use in karyomapping. Illumina remains committed to providing customers with high-quality support and service.
VeriSeq PGS Kit
A next-generation sequencing solution that provides accurate chromosome screening for identification of in vitro embryos most likely to be euploid.
TruSight One Sequencing Panels
Comprehensive sequencing research panels targeting disease-associated regions of the exome with high analytical sensitivity and specificity.
TruSight Hereditary Cancer Panel
Targeted sequencing panel that assesses germline mutations across 113 genes and 125 SNPs associated with genetic cancer risk predisposition.
References
- International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789-796.